

*Petition for Inter Partes Review
of U.S. Patent No. 8,772,306*

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.
Petitioner

v.

JAZZ PHARMACEUTICALS, INC.
Patent Owner

Case IPR: Unassigned
Patent 8,772,306

**PETITION FOR INTER PARTES REVIEW OF U.S. PATENT NO. 8,772,306
UNDER 35 U.S.C. § 311–319 AND 37 C.F.R. § 42.1–.80, 42.100–.123**

Mail Stop “PATENT BOARD”
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Table of Contents

I. INTRODUCTION AND STATEMENT OF RELIEF REQUESTED (37 C.F.R. § 42.22(a))	1
II. GROUNDS FOR STANDING (37 C.F.R. § 42.104(a)).....	1
III. STATEMENT OF THE PRECISE RELIEF REQUESTED AND THE REASONS THEREFOR.....	2
IV. OVERVIEW.....	2
A. Person of Ordinary Skill In The Art.....	2
B. State of the Art.....	3
1. Background Regarding GHB	3
2. Background Regarding Divalproex Sodium	4
3. Background Regarding Drug Interactions	5
4. Background Regarding GHB/Valproate Interactions	7
5. The '306 Patent	11
V. CLAIM CONSTRUCTION	13
A. “Concomitant” and “Concomitantly”.....	14
VI. IDENTIFICATION OF CHALLENGE.....	14
A. Identification of Prior Art.....	15
B. Each of the References Cited is Prior Art.	16
1. The FDA Guidance (PAR1011) Qualifies as Prior Art.	17
2. Xyrem Label (PAR1006) Qualifies as Prior Art.....	18
3. Cagnin, Waszkielewicz, Weiss, and the Depakote 2011 Label Qualify as Prior Art.	18
C. Ground I: Claims 1-34 Are Obvious Over the Xyrem 2005 Label, the Depakote 2011 Label, Cagnin, Waszkielewicz, and the FDA Guidance.....	18
1. Comparison of the '306 Patent Claims to the Prior Art: Claim 1	22
2. Claim 11	27
3. Claim 19	28
4. Claims 30 and 33	30
5. Claims 2, 4, 12, 13, 18, and 28.....	32

*Petition for Inter Partes Review
of U.S. Patent No. 8,772,306*

6. Claims 3 and 8.....	34
7. Claims 5 and 16.....	35
8. Claims 6, 17, and 27.....	35
9. Claims 7, 9, and 10.....	36
10. Claims 14, 15, 20, and 21.....	37
11. Claims 22 and 24.....	39
12. Claim 25.....	39
13. Claim 26.....	39
14. Claim 31.....	40
15. Claims 23, 29, 32 and 34.....	40
D. Ground 2: Claims 1-34 Are Obvious Over the Xyrem 2005 Label in view of Cagnin, Waszkielewicz, Weiss, the Depakote 2011 Label, and the FDA Guidance.....	41
1. Comparison of the '306 Patent Claims to the Prior Art: Claim 1.....	44
2. Claim 11.....	47
3. Claim 19.....	48
4. Claim 30 and 33.....	49
5. Claims 2, 4, 12, 13, 18, and 28.....	50
6. Claims 3 and 8.....	50
7. Claims 5 and 16.....	50
8. Claims 6, 17, and 27.....	51
9. Claims 7, 9, and 10.....	51
10. Claims 14, 15, 20, and 21.....	52
11. Claims 22 and 24.....	53
12. Claim 25.....	53
13. Claim 26.....	54
14. Claim 31.....	54
15. Claims 23, 29, 32 and 34.....	54
E. Secondary Considerations Do Not Rebut the <i>Prima Facie</i> Case.....	54

*Petition for Inter Partes Review
of U.S. Patent No. 8,772,306*

II. IT IS MORE LIKELY THAN NOT THAT PETITIONER WILL PREVAIL
WITH RESPECT TO AT LEAST ONE OF THE CHALLENGED CLAIMS59

IV. CONCLUSION60

...

I. INTRODUCTION AND STATEMENT OF RELIEF REQUESTED (37 C.F.R. § 42.22(A))

Par Pharmaceutical, Inc. (“Par” or “Petitioner”) submits this Petition for *Inter Partes* review (“IPR”) seeking cancellation of claims 1-34 of U.S. Patent No. 8,772,306 (“the ’306 patent”) (PAR1001) as unpatentable under 35 U.S.C. §103(a) in view of the prior art. According to Office records, the ’306 patent is assigned to Jazz Pharmaceuticals Ireland Limited, though Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Limited (collectively, “Jazz”) have represented they together own the patent.¹ Every limitation of the claims of the ’306 patent would have been obvious to a person of skill in the art (“POSA”) based on prior art printed publications, as set forth below in Grounds 1 and 2.

For the reasons explained below, Petitioner is at least reasonably likely to prevail on the asserted Ground with respect to the challenged claims. Therefore, Petitioners respectfully request that this Board institute IPR and cancel each of challenged claims 1–34 of the ’306 patent.

II. GROUNDS FOR STANDING (37 C.F.R. § 42.104(A))

Petitioners certify that the ’306 patent is available for IPR and Petitioner is not barred or estopped from requesting IPR of any of the challenged claims.

¹ See D.I. 1, ¶ 10 in *Jazz Pharmaceuticals, Inc. v. Par Pharmaceutical, Inc.*, C.A.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.